|
EIF1AX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62725388719309E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.14557277395033E-13 |
| Normal-vs-Stage2 |
5.5217999999968E-05 |
| Normal-vs-Stage3 |
8.72635297355373E-13 |
| Normal-vs-Stage4 |
1.4432899320127E-15 |
| Stage1-vs-Stage2 |
1.585180E-01 |
| Stage1-vs-Stage3 |
6.088400E-02 |
| Stage1-vs-Stage4 |
1.54650999999451E-05 |
| Stage2-vs-Stage3 |
1.605730E-02 |
| Stage2-vs-Stage4 |
4.13510000000228E-05 |
| Stage3-vs-Stage4 |
1.441590E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.36557432028894E-14 |
| Normal-vs-AfricanAmerican |
1.60459999999363E-05 |
| Normal-vs-Asian |
3.93850000390827E-08 |
| Caucasian-vs-AfricanAmerican |
6.363200E-01 |
| Caucasian-vs-Asian |
7.397000E-01 |
| AfricanAmerican-vs-Asian |
5.977400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
2.49450016198693E-10 |
| Male-vs-Female |
<1E-12 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.49870124591212E-11 |
| Normal-vs-Age(41-60Yrs) |
1.54065649127233E-12 |
| Normal-vs-Age(61-80Yrs) |
4.11404244005098E-12 |
| Normal-vs-Age(81-100Yrs) |
2.207400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.127400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.880400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.311400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.317240E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.014400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.664000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.162100E-02 |
| Classical-VS-Follicular |
6.468200E-01 |
| Classical-VS-Other |
2.687200E-01 |
| Classical-VS-Normal |
1.99973371195483E-12 |
| Tall-VS-Follicular |
7.682500E-02 |
| Tall-VS-Other |
8.335000E-01 |
| Tall-VS-Normal |
8.75630001839767E-09 |
| Follicular-VS-Other |
2.566400E-01 |
| Follicular-VS-Normal |
4.07610000197067E-08 |
| Other-VS-Normal |
7.577800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.60700375018541E-11 |
| Normal-vs-N1 |
9.65560964516499E-13 |
| N0-vs-N1 |
1.531640E-02 |
|
|
